NVIC called on the FDA to legally require vaccine manufacturers to adhere to binding regulations rather than offering companies non-binding recommendations and to immediately recommend the use of RotaTeq vaccine be suspended until Merck can guarantee it is free of PCV1 and PCV2 and other adventitious agents.
NVIC has also asked FDA to institute stronger legal requirements for proof that vaccine cell substrates and other animal products used for production of seed stocks are free from adventitious agent contamination and that vaccines remain clean before being released. Institute stricter labeling standards to fully and clearly inform the public using vaccines about residual adventitious agent content of all vaccines.
Barbara Loe Fisher, co-founder and president of NVIC, said: “The contamination of rotavirus vaccines with animal virus DNA that was not detected pre or post-licensure is an important wake up call for industry and government. Parents being told by federal officials to give their babies Rotarix and RotaTeq vaccine expect those vaccines and others to be free from adventitious agent contamination.”
Vicky Debold, director of research and patient safety at NVIC, who is also the consumer member of the FDA vaccine advisory committee, urged the FDA to continue to adhere to the precautionary principle and be transparent in its process whenever contaminants are detected in vaccines.